Gilead Sciences said Thursday that it has exercised an option to license four cancer drugs from Arcus Biosciences, including an immunotherapy that works against a closely followed anti-cancer target called TIGIT.
In exchange for licensing rights to the four cancer drugs, Gilead is paying Arcus $725 million. The two companies will co-develop the drugs, share costs, and if approved, split profits in the U.S., the companies said.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
